Metreleptin
| Clinical data | |
|---|---|
| Trade names | Myalept |
| Legal status | |
| Legal status |
|
| Identifiers | |
| Synonyms | Mettreleptin; N-Methionylleptin; r-metHuLeptin |
| CAS Number | 186018-45-1 |
| DrugBank |
DB09046  |
| ChemSpider | none |
| UNII |
TL60C27RLH |
| Chemical and physical data | |
| Formula | C714H1167N191O221S6 |
| Molar mass | 16,156 g/mol |
Metreleptin (Myalept) is a synthetic analog of the hormone leptin used to treat diabetes and various forms of dyslipidemia. It is has been approved in Japan for metabolic disorders including lipodystrophy and in the United States as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.[1]
Metreleptin is currently being investigated for the treatment of diabetes and/or hypertriglyceridemia, in patients with rare forms of lipodystrophy, syndromes characterized by abnormalities in adipose tissue distribution, and severe metabolic abnormalities.[2]
In a three-year study of metreleptin in patients with lipodystrophy organized by the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, metreleptin treatment was associated with a significant decrease in blood glucose (A1c decreased from 9.4% at baseline to 7.0% at study end) and triglyceride concentration (from 500 mg/dl at baseline to 200 mg/dl at study end).[3]
References
- ↑ Chou K, Perry CM (2013). "Metreleptin: first global approval". Drugs. 73 (9): 989–997. doi:10.1007/s40265-013-0074-7. PMID 23740412.
- ↑ "Amylin Seeks FDA Approval for Metreleptin". diabetesincontrol.com. 11 April 2012.
- ↑ "Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy". Press Release. Amylin Pharmaceuticals. 2011-04-15. Retrieved 2011-10-27.